STIPULATION AND ORDER APPOINTING CO-LEAD PLAINTIFFS AND CO-LEAD COUNSEL - 1 Case No. 2:25-cv-00512-BJR 1

4

5 6

7

8 9

10

11 12

13

14

15

16

17

18

19

20 21

22

23

24

25

26 27

Lead Plaintiff Movants Shane Honey ("Honey") and Jonatan Koskinen ("Koskinen"), by and through their undersigned counsel, hereby stipulate as follows in support of their request for appointment as Co-Lead Plaintiffs and approval of their selection of Co-Lead Counsel:

WHEREAS, on March 21, 2025, the above-captioned action (the "Action") was commenced, alleging violations of the federal securities laws on behalf of a putative class consisting of investors in the securities of Sana Biotechnology, Inc. ("Sana") (see Dkt. No. 1);

WHEREAS, as a putative class action alleging violations of the federal securities laws, this Action is governed by the Private Securities Litigation Reform Act of 1995 (the "PSLRA"), which provides, in relevant part, that any putative Class member may move for appointment as Lead Plaintiff in the Action within 60 days of publication of notice of the pendency of the Action—here, on or before May 20, 2025 (15 U.S.C. § 78u-4(a)(3)(B)(iii)(I)(aa));

WHEREAS, on May 20, 2025, two members of the putative Class alleged in the Action-Honey and Koskinen—filed timely, separate motions seeking appointment as Lead Plaintiff in the Action and approval of their respective selections of Lead Counsel for the Action (the "Lead Plaintiff Motions") (Dkt. Nos. 17, 20);

WHEREAS, the PSLRA provides, *inter alia*, that the most adequate plaintiff to serve as Lead Plaintiff is, in the determination of the Court, the "person or group of persons" that has the largest financial interest in the relief sought by the class and otherwise satisfies the relevant requirements of Rule 23 of the Federal Rules of Civil Procedure ("Rule 23") (15 U.S.C. § 78u-4(a)(3)(B)(iii));

WHEREAS, the PSLRA provides that, subject to the approval of the Court, the most adequate plaintiff will select and retain counsel to represent the class (15 U.S.C. § 78u-4(a)(3)(B)(v);

28

WHEREAS, Honey and Koskinen have each provided sworn Certifications pursuant to the PSLRA in support of their respective applications for Lead Plaintiff appointment, setting forth, *inter alia*, their transactions in Sana securities (*see* Dkt. Nos. 18-2, 21-2);

WHEREAS, Honey is a sophisticated investor with 20 years of investing experience, who invested solely in Sana options and claims to have sustained approximately \$37,190 in losses as a result of Defendants' alleged wrongful conduct (*see* Dkt. No. 18-3; Dkt. No. 17 at \*4, 8);

WHEREAS, Koskinen, a sophisticated individual investor with 5 years of investing experience that invested solely in Sana common stock, claims to have sustained approximately \$7,087 in losses as a result of Defendants' alleged wrongful conduct (*see* Dkt. No. 21-1; Dkt. No. 21-3 at 1 ¶ 2; Dkt. No. 20 at 2, 5, 7);

WHEREAS, accordingly, Honey and Koskinen have each alleged a significant financial interest in the outcome of this litigation;

WHEREAS, Honey and Koskinen are also each qualified to serve as Lead Plaintiffs in this case given, among other things, their respective Lead Plaintiff Motion submissions (Dkt. Nos. 17-18, 20-21);

WHEREAS, having reviewed one another's submissions to the Court, Honey and Koskinen believe that they each satisfy the typicality and adequacy requirements of Rule 23;

WHEREAS, after reviewing each other's submissions to the Court, Honey and Koskinen—as the only movants in contention for appointment as Lead Plaintiff—have decided that it is in the best interests of the Class to join together as Co-Lead Plaintiffs and for their respective selections of The Rosen Law Firm, P.A. ("Rosen Law") and Pomerantz LLP ("Pomerantz") to serve as Co-Lead Counsel in that it will, *inter alia*, provide broader representation to class members as common stock and options investors will be separately represented by Koskinen and Honey,

28 |

24

25

26

27

2

1

4

5

7

8 9

1011

12

13 14

15

16

1718

19

20

21

22

23

24

2526

27

28

STIPULATION AND ORDER APPOINTING CO-LEAD PLAINTIFFS AND CO-LEAD COUNSEL - 4

COUNSEL - 4 Case No. 2:25-cv-00512-BJR

respectively; allow their counsel to pool their resources to immediately and efficiently commence prosecution of this Action; and avoid further delay associated with a protracted lead plaintiff dispute;

WHEREAS, Honey and Koskinen have decided that it is in the best interests of the class for Badgley Mullins Turner PLLC, a firm experienced in the local rules and customs of this District, to serve as liaison counsel;

WHEREAS, Honey and Koskinen are committed to supervising the conduct of this litigation by their counsel and to ensuring that counsel coordinate appropriately, prosecute the action efficiently, and avoid any duplication of effort in the conduct of the litigation;

WHEREAS, courts have endorsed stipulations among competing Lead Plaintiff movants, like here, as promoting the statutory purposes of the PSLRA, and have permitted "independent lead plaintiff movants [to] join together to help ensure that adequate resources and experience are available to the prospective class in the prosecution of th[e] action and because [e]mploying a colead plaintiff structure . . . will also provide the proposed class with the substantial benefits of joint decision-making." *In re Rockwell Med., Inc. Sec. Litig.*, No. 1:16-cv-01691-RJS, Dkt. No. 18 at 2-3 (S.D.N.Y. May 20, 2016) (internal quotation marks omitted) (citing *Pirelli Armstrong Tire Corp. Retiree Med. Benefits Tr. v. LaBranche & Co.*, 229 F.R.D. 395, 420 (S.D.N.Y. 2004)); *see also Deputy v. Akebia Therapeutics, Inc. et al.*, No. 1:22-cv-01411-AMD-VMS (E.D.N.Y.), ECF Order on June 28, 2022 (approving stipulation of competing lead plaintiff movants to serve as co-lead plaintiffs and approving their selection of co-lead counsel); *In re Grab Holdings Ltd. Sec. Litig.*, No. 1:22-cv-02189-VM (S.D.N.Y.), Dkt. No. 39 (same); *In re Altimmune, Inc. Sec. Litig.*, No. 8:24-cv-01315-ABA (D. Md.), Dkt. No. 22 (same); *Pizzuto v. Homology Meds., Inc.*, No. 2:22-cv-01968-FLA-JPR (C.D. Cal.), Dkt. No. 38 (same); *Maurer v. Argos Therapeutics Inc., et al.*, No. 1:17-cv-

00216-TDS-LPA (M.D.N.C.), Dkt. No. 26 (same); In re Facebook, Inc. Sec. Litig., No. 5:18-cv-1 2 01725-EJD, Dkt. No. 56 at 2-3 (N.D. Cal. Aug. 3, 2018) (approving stipulation of lead plaintiff 3 movants where movants "concluded that a protracted dispute concerning lead plaintiff appointment 4 . . . [was] not in the best interests of the class and that jointly prosecuting [the] litigation would be 5 appropriate and assist with the speedy commencement of [the] litigation"); see also In re Millennial 6 Media, Inc. Sec. Litig., 87 F. Supp. 3d 563, 570 (S.D.N.Y. 2015) ("A co-lead plaintiff structure best 7 protects the interests of the class . . . and gives the class the advantages of the combined knowledge, 8 9 experience, and judgment of both lead plaintiffs." (collecting cases)); and 10 WHEREAS, Pomerantz and Rosen Law have successfully prosecuted similar securities 11 class actions under the PSLRA as Co-Lead Counsel. See, e.g., In re Blue Apron Holdings, Inc. 12 Securities Litigation, No. 17-cv-04846-NGG-PK (E.D.N.Y.); Pirnik v. Fiat Chrysler Automobiles 13 N.V. et al., No. 1:15-cv-07199-JMF (S.D.N.Y.); Whiteley, et al. v. Zynerba Pharmaceuticals, Inc., 14 et al., No. 2:19-cv-04959-NIQA (E.D. Pa.); Chan, et al., v. New Oriental Education & Technology 15 16 Group Inc., et al., No. 2:16-cv-09279-KSH-CLW (D.N.J.); Ortiz v. Canopy Growth Corp., et al., 17 case no. 2:19-cv-20543-KM-ESK (D.N.J.); Vataj v. Johnson, et al., No. 4:19-cv-06996-HSG (N.D. 18 Cal.); Thomas, et al., v. MagnaChip Semiconductor Corp., et al., No. 3:14-CV-01160-JST (N.D. 19 Cal.); Thorpe, et al., v. Walter Investment Management Corp., No. 1:14-cv-20880-UU (S.D. Fla.); 20 21 22 23 24 25 26 27 28

STIPULATION AND ORDER APPOINTING CO-LEAD PLAINTIFFS AND CO-LEAD COUNSEL - 5 Case No. 2:25-cv-00512-BJR BADGLEY MULLINS TURNER PLLC 19910 50<sup>th</sup> Avenue W., Suite 103 Lynnwood, WA 98036 TEL 206.621.6566

IT IS HEREBY STIPULATED AND AGREED THAT, subject to the Court's approval, as 1 2 follows: 3 1. 4 5 6 IN RE SANA BIOTECHNOLOGY, INC. 7 SECURITIES LITIGATION 8 THIS DOCUMENT RELATES TO: 9 10 2. 11 12 13 14 15 16 3. 17 18 19 4(a)(3)(B); and 20 21 4. 22 23 IT IS SO STIPULATED. 24 Dated: May 29, 2025 25 26 27 28

Every pleading in this Action shall bear the following Caption:

## UNITED STATES DISTRICT COURT WESTERN DISTRICT OF WASHINGTON AT SEATTLE

Case No. 2:25-cv-00512-BJR CLASS ACTION [TITLE OF DOCUMENT]

- When the document being filed pertains to all actions, the phrase "All Actions" shall appear immediately after the phrase "This Document Relates To:". When the document applies to some, but not all, of the actions, the document shall list, immediately after the phrase "This Document Relates To:", the docket number for each individual action to which the document applies, along with the name of the first-listed plaintiff in said action;
- Honey and Koskinen's Lead Plaintiff Motions (Dkt. Nos. 17, 20) are granted and Honey and Koskinen are hereby appointed Co-Lead Plaintiffs in this Action and any subsequently filed or transferred actions that are consolidated with this Action, pursuant to 15 U.S.C. § 78u-
- Co-Lead Plaintiffs' selections of Pomerantz and Rosen Law as Co-Lead Counsel and Badgley Mullins Turner PLLC as liaison counsel are hereby approved.

Respectfully submitted,

## BADGLEY MULLINS TURNER PLLC

By: /s/ Duncan C. Turner Duncan C. Turner, WSBA No. 20597

STIPULATION AND ORDER APPOINTING CO-LEAD PLAINTIFFS AND CO-LEAD

COUNSEL - 6

Case No. 2:25-cv-00512-BJR

BADGLEY MULLINS TURNER PLLC

19910 50th Avenue W., Suite 103 Lynnwood, WA 98036 TEL 206.621.6566

1	19910 50th Ave. W., Suite 103
2	Lynnwood, WA 98036
_	Telephone: (206) 621-6566
3	dturner@badgleymullins.com
4	Liaison Counsel for Movants Jonatan Koskinen and
_	Shane Honey and Proposed Liaison Counsel for the
5	Class
6	THE ROSEN LAW FIRM, P.A.
7	/ / DI :III - YZ
0	/s/ Phillip Kim Phillip Kim, Esq.
8	(pro hac vice application forthcoming)
9	Laurence M. Rosen, Esq.
	(pro hac vice application forthcoming)
10	275 Madison Avenue, 40th Floor
11	New York, New York 10016
	Telephone: (212) 686-1060
12	Facsimile: (212) 202-3827 philkim@rosenlegal.com
13	lrosen@rosenlegal.com
14	
14	Counsel for Shane Honey and Proposed Co-Lead
15	Counsel for the Class
16	POMERANTZ LLP
17	/s/ Jeremy A. Lieberman
18	Jeremy A. Lieberman
10	(pro hac vice application forthcoming)
19	J. Alexander Hood II
20	(pro hac vice application forthcoming) 600 Third Avenue, 20th Floor
20	New York, New York 10016
21	Telephone: (212) 661-1100
,,	Facsimile: (917) 463-1044
22	jalieberman@pomlaw.com
23	ahood@pomlaw.com
24	Counsel for Jonatan Koskinen and Proposed Co-
	Lead Counsel for the Class
25	DDANGTEIN CEWIDTZ 9.
26	BRONSTEIN, GEWIRTZ & GROSSMAN, LLC
27	Peretz Bronstein
28	STIDLIL ATION AND ODDED ADDOINTING RADGLEY MILLINS THRNER PLIC

STIPULATION AND ORDER APPOINTING CO-LEAD PLAINTIFFS AND CO-LEAD COUNSEL - 7 Case No. 2:25-cv-00512-BJR

1	(pro hac vice application forthcoming) 60 East 42nd Street, Suite 4600
2	New York, New York 10165
3	Telephone: (212) 697-6484 Facsimile: (212) 697-7296
4	peretz@bgandg.com
5	Additional Counsel for Jonatan Koskinen
6	
7	
8	
9	
10	
11	PURSUANT TO STIPULATION, IT IS SO ORDERED.
12	
13	DATED: June 2, 2025.
14	_
15	Barbara Lottetin
16	The Honorable Barbara J. Rothstein
17	United States Judge
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
ı	

STIPULATION AND ORDER APPOINTING CO-LEAD PLAINTIFFS AND CO-LEAD COUNSEL - 8 Case No. 2:25-cv-00512-BJR

28